帕利珠单抗真实世界有效性:加拿大安大略省1993-2017年人群研究
结果显示最高危组(符合条件且<6月龄婴儿)严重RSV相关疾病发生率下降65.4%(从230.6降至79.8例/1000儿童年),1998年全国项目引入后符合条件的<6月龄婴儿相对不符合条件者发生率下降10.4%(95%CI -18.6%至39.4%)。低收入社区婴儿初始发生率较高,但符合条件<6月龄婴儿中收入别发生率随时间趋同,其他儿童未见此趋同。
要点
- 最高危组(符合条件且<6月龄)严重RSV相关疾病发生率研究期间下降65.4%。
- 1998年国家帕利珠单抗项目引入后,符合条件<6月龄婴儿相对不符合者发生率下降10.4%(95%CI -18.6%至39.4%)。
- 符合条件<6月龄婴儿中低收入与高收入社区发生率随时间趋同,其他儿童未见趋同。
核心结论
- 研究期间严重RSV相关疾病发生率下降,时间与幅度提示帕利珠单抗可能减轻RSV负担并缩小符合条件婴儿的社会不平等,但不能断定因果。
主要发现
- 最高危组(符合条件<6月龄婴儿)严重RSV相关疾病发生率从230.6降至79.8例/1000儿童年,下降65.4%。
- 1998年国家帕利珠单抗项目引入后,符合条件<6月龄婴儿相对不符合条件<6月龄婴儿的严重RSV相关疾病发生率变化下降10.4%(95%CI -18.6%至39.4%)。
- 低收入社区婴儿初始严重RSV相关疾病发生率较高,但符合条件<6月龄婴儿中收入别发生率随时间趋同,其他儿童未见趋同。
关键数值与推荐
- 帕利珠单抗符合条件:极早产且RSV季节时≤6月龄;<24月龄伴显著慢性肺病或先天性心脏病;或≤6月龄早产或偏远地区居民。
- 主要结局严重RSV相关疾病定义为因毛细支气管炎、RSV肺炎或RSV诊断而住院或死亡。
临床怎么用
- 研究结果支持帕利珠单抗项目在高危婴儿中可能降低严重RSV相关疾病负担并缩小收入相关不平等,临床可据此评估高危婴儿预防策略。
- 因不能断定因果,临床决策应结合个体风险与指南,并注意低收入社区婴儿初始风险较高。
局限性
- 研究为观察性设计,不能断定帕利珠单抗与结局下降之间的因果关系。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effectiveness of two palivizumab programmes targeting high-risk infants, defined by prematurity, diagnosis of comorbidities and geography, and assess potential disparities by neighbourhood income. DESIGN: Controlled, interrupted time series. SETTING: Ontario, Canada. PATIENTS: We used linked health and demographic administrative databases to identify all children born in hospitals 1 January 1993 through 31 December 2016. Follow-up ended at the earliest of second birthday or 30 June 2017. INTERVENTION: Palivizumab-eligibility: child was born very preterm and ≤6 months old during respiratory syncytial virus (RSV) season; <24 months old with significant chronic lung or congenital heart disease; or ≤6 months, born preterm or residents of remote regions. MAIN OUTCOME: Severe RSV-related illness, defined as hospitalisation or death with a diagnosis of bronchiolitis, RSV pneumonia or RSV. RESULTS: 3 million births and 87 000 RSV-related events were identified. Over the study period, rates of severe RSV-related illness declined 65.4% among the highest risk group, eligible infants <6 months (230.6 to 79.8 admissions per 1000 child-years). Relative to changes among ineligible infants <6 months, rates dropped 10.4% (95% CI -18.6% to 39.4%) among eligible infants immediately following introduction of a national palivizumab programme in 1998. Initially, rates were considerably higher among infants from low-income neighbourhoods, but income-specific rates converged over time among eligible infants <6 months; such convergence was not seen among other children. CONCLUSIONS: Incidence of severe RSV-related illness declined over the study period. While we cannot attribute causality, the timing and magnitude of these declines suggest impact of palivizumab in reducing RSV burden and diminishing social inequities among palivizumab-eligible infants.
引用
- Fitzpatrick T, McNally JD, Stukel TA, et al. Palivizumab's real-world effectiveness: a population-based study in Ontario, Canada, 1993-2017. Arch Dis Child. 2020. PMID: 32859612. doi:10.1136/archdischild-2020-319472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。